On December 20, 2017 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective cancer medicines, reported that Drew Fromkin, President and Chief Executive Officer, will present at the 10th Annual Biotech Showcase, occuring January 8-10, 2018 at the Hilton Union Square in San Francisco (Press release, Tarveda Therapeutics, DEC 20, 2017, View Source [SID1234522746]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will take place at 10:00am Pacific Time on Wednesday, January 10 in Franciscan – D.
In the presentation, Mr. Fromkin will address the Company’s Pentarin miniature drug conjugate platform including PEN-221, which is currently in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) positive cancers including neuroendocrine and small cell lung cancers, and PEN-866, an HSP90 targeting conjugate, which is being developed for the treatment of patients with a wide range of solid tumors including pancreatic cancer, small cell lung cancer and sarcoma.
About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell‑killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell‑killing payload inside the cancer cells for efficacy.